Vistagen Therapeutics Inc (VTGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -69,685 | -53,411 | -34,512 | -15,095 | -51,418 |
| Depreciation Amortization | -344 | -265 | -177 | -85 | -239 |
| Other Working Capital | -377 | 396 | 111 | -4,628 | 5,371 |
| Other Operating Activity | 3,970 | 3,044 | 1,973 | 962 | 4,189 |
| Operating Cash Flow | $-66,436 | $-50,236 | $-32,605 | $-18,846 | $-42,097 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -726 | -627 | -757 | -723 | -12,957 |
| PPE Investments | -151 | -151 | -125 | -65 | -191 |
| Investing Cash Flow | $-877 | $-778 | $-882 | $-788 | $-13,148 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 1,020 | 1,020 | 1,020 | 1,020 | N/A |
| Debt Repayment | -925 | -642 | -364 | -90 | N/A |
| Common Stock Issued | 30,876 | 30,876 | 28,486 | 558 | 3,210 |
| Financing Cash Flow | $30,971 | $31,254 | $29,142 | $1,488 | $3,210 |
| Beginning Cash Position | 67,131 | 67,131 | 67,131 | 67,131 | 119,166 |
| End Cash Position | 30,789 | 47,371 | 62,786 | 48,985 | 67,131 |
| Net Cash Flow | $-36,342 | $-19,760 | $-4,345 | $-18,146 | $-52,035 |
| Free Cash Flow | |||||
| Operating Cash Flow | -66,436 | -50,236 | -32,605 | -18,846 | -42,097 |
| Capital Expenditure | -151 | -151 | -125 | -65 | -191 |
| Free Cash Flow | -66,587 | -50,387 | -32,730 | -18,911 | -42,288 |